Lucchi-Angellier E
Service d'oncologie, hôpital Fontenoy, BP 407, 28018 Chartres, France.
Rev Med Interne. 2001 Dec;22(12):1213-24. doi: 10.1016/s0248-8663(01)00493-3.
Tamoxifen as adjuvant hormonal therapy after hormonosensitive-breast cancer surgery is well established nowadays, as well as its efficacy in first-line therapy of advanced hormonosensitive breast cancers. Research of drugs which could be effective, with little toxicity, and having a positive impact on cardiovascular disease or bone is an important issue.
New drugs are in development or will soon be on the market to permit second or third lines of treatment with respect to effectiveness and quality of life, such as new anti-estrogens or selective estrogen receptors modulators or aromatase inhibitors. Their principal characteristics are reviewed through recent data.
Prevention of breast cancer is a pertinent question and major publications are presented. Finally, the controversy about the possible reintroduction of replacement hormonal therapy after breast cancer will be questioned through trials.
如今,他莫昔芬作为激素敏感性乳腺癌手术后的辅助激素治疗已得到充分确立,其在晚期激素敏感性乳腺癌一线治疗中的疗效也是如此。研发疗效显著、毒性小且对心血管疾病或骨骼有积极影响的药物是一个重要问题。
正在研发或即将上市的新药有望在有效性和生活质量方面用于二线或三线治疗,如新的抗雌激素药物、选择性雌激素受体调节剂或芳香化酶抑制剂。通过近期数据对它们的主要特性进行了综述。
乳腺癌预防是一个相关问题,并介绍了主要出版物。最后,将通过试验对乳腺癌后是否可能重新引入替代激素治疗的争议提出质疑。